ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

イソソルビド

Isosorbide

HCID 12597
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
652-67-5
標準SMILES
O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2O
InChIKey
KLDXJTOLSGUMSJ-JGWLITMVSA-N
分子式
C6H10O4
平均分子量
146.14 g/mol
単同位体質量
146.0579088

概要

Isosorbide is an organic molecular entity.

名称と識別子

優先名称
Isosorbide
IUPAC
(3S,3aR,6R,6aR)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3,6-diol
現地名
イソソルビド
英語名
Isosorbide
分子式
C6H10O4
分子量
146.14

名称と別名

isosorbide652-67-5IsobideDevicoran1,4:3,6-Dianhydro-D-glucitolHydronolIsmotic(3R,3aR,6S,6aR)-hexahydrofuro[3,2-b]furan-3,6-diol(+)-D-IsosorbideD-Glucitol, 1,4:3,6-dianhydro-1,4:3,6-Dianhydrosorbitol1,4:3,6-Dianhydro-D-sorbitol
名称をさらに表示
イソソルビドヒドロノールイソバイド-DSデビコランイソバイド(3S,3aα,6aα)-ヘキサヒドロフロ[3,2-b]フラン-3α,6β-ジオール(3S,3aR,6R,6aR)-ヘキサヒドロフロ[3,2-b]フラン-3,6-ジオール(3R,3aα,6aα)-ヘキサヒドロフロ[3,2-b]フラン-3β,6α-ジオール1,4:3,6-ジアンヒドロ-D-グルシトールイソビド1,4:3,6-ジアンヒドロ-D-ソルビトール(+)-D-イソソルビドメニレット(3aα,6aα)-ヘキサヒドロフロ[3,2-b]フラン-3α,6β-ジオール2,3,3aα,5,6,6aα-ヘキサヒドロフロ[3,2-b]フラン-3α,6β-ジオール1,4:3,6-ジアンヒドロソルビトール1,4:3,6-ジアンヒドログルシトールD-イソソルビドイソソルビド (75% SOLUTION)ジアンヒドロ-D-グルシトールat101Isosorbide (75% solution, 1 g)ucitoLIsosorbidNSC 40725
DTXSID5046196NSC-40725Glucitol, 1,4:3,6-dianhydro-, D-WXR179L51SNSC40725DTXCID3026196(3R,3aR,6S,6aR)-hexahydrofuro(3,2-b)furan-3,6-diolRefChem:55420

データベース識別子

CAS
652-67-5
PubChem CID
12597
DTXSID
DTXSID5046196
ChEMBL
CHEMBL1200660
ChEBI
CHEBI:6060
UNII
WXR179L51S
EC Number
211-492-3
Nikkaji
J7.077G

物性

構造計算による物性

XLogP
-1.4
極性表面積
58.9 Ų
水素結合供与体数
2
水素結合受容体数
4
回転可能結合数
0
重原子数
10
形式電荷
0
複雑度
122

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
Color/FormCRYSTALS
Human Drugs · 2 件

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point · 2 件

60-63

61-64 °C

Food Contact SubstancesFCS -> FDA Cumulative Estimated Daily Intake (CEDI)
Optical RotationSPECIFIC OPTICAL ROTATION: +44 DEG/D
Physical DescriptionLiquid; Dry Powder; Liquid

物理化学的性質

融点
60 · 60-63 °C (lit.)
比旋光度
42 · 42 º (c=3, H2O)
沸点
175 °C/2mmHg · 175°C/2mmHg(lit.)
比重(密度)
1.0945 · 1.0945 (rough estimate)
蒸気圧
0.007 Pa · 0.007Pa at 20℃

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 3 件

This chemical does not meet GHS hazard criteria for 99.3% (145 of 146) of all reports.

Not Classified

Aggregated GHS information provided per 146 reports by companies from 2 notifications to the ECHA C&L Inventory.

危険有害性情報

Regulatory Information · 6 件

Chemical: D-Glucitol, 1,4:3,6-dianhydro-

Regulation (EC) No 1935/2004 (amended)

D-Glucitol, 1,4:3,6-dianhydro- is listed on the EPA's Chemical Data Reporting (CDR) system. Manufacturers and importers of D-Glucitol, 1,4:3,6-dianhydro- are required to report information about their production and use of this chemical to the EPA under the Toxic Substances Control Act (TSCA). (40 eCFR Part 711)

PMN - indicates a commenced PMN (Pre-Manufacture Notices) substance.

REACH registered substance: 1,4:3,6-dianhydro-D-glucitol (EC: 211-492-3)

D-Glucitol, 1,4:3,6-dianhydro-: Does not have an individual approval but may be used under an appropriate group standard

Hazard Classes and CategoriesNot Classified

毒性情報

Adverse Effects · 1 件

The adverse effects of isosorbide are due to the vasodilation of the venous capacitance vessels and the arterioles. The venodilation results in peripheral pooling of blood and arteriolar dilation, lowering systemic vascular resistance (afterload) and lowering blood pressure. Other adverse effects can be due to the reflex activity of the sympathetic nervous system due to vasodilation.

Toxicity Summary · 2 件

IDENTIFICATION: Isosorbide dinitrate is a vasodilator, anti-anginal drug. Isosorbide dinitrate is a fine white to ivory-white odorless crystalline solid. It is sparingly soluble in water; freely soluble in acetone, chloroform, alcohol and ether. Indications: Isosorbide dinitrate is used principally in the management of patients with ischemic heart disease. It reduces the number, duration and severity of episodes of angina pectoris. Exercise tolerance is increased and the requirements for nitroglycerin are reduced. It is effective in all forms of angina, (stable effort angina, mixed angina, unstable angina and vasospastic or variant angina). It is used in acute myocardial infarction in control of ischemic pain, reduction of elevated blood pressure and in the treatment of pulmonary edema and congestive cardiac failure. It is also useful in the treatment of severe hypertension. The iv infusion can be used for precise control of blood pressure. It is used to control blood pressure during general anesthesia when precise control of blood pressure is important. It may also be used in esophageal spasm. HUMAN EXPOSURE: Main risks and target organs: Vasodilatation and hypotension (with their accompanying complications) are the main risks with overdose of isosorbide dinitrate. Heart and blood vessels are the target organs. Methemoglobinemia can occur. Summary of clinical effects: Features of poisoning may appear within few minutes to one hour or more after exposure. Tachycardia, hypotension followed by bradycardia and collapse, throbbing headache, dizziness, restlessness, syncope, convulsions and coma could occur. Some of the other features that can be seen include vomiting, diarrhea, cyanosis and methemoglobinemia. Respiratory failure may occur in severe cases. Clinical diagnosis is based on the history of exposure, and signs and symptoms observed: tachycardia, hypotension, throbbing headache, flushing of the face. Contraindications: Hypersensitivity to isosorbide dinitrate. Pre-existing methemoglobinemia. Marked anemia, head trauma or cerebral hemorrhage. Routes of entry: Oral: Oral entry and absorption through gastro-intestinal tract is the most frequent route of intoxication. Absorption can occur sublingually. Dermal: A preliminary report of experience with isosorbide dinitrate cream is available. Parenteral: Intoxication may occur in patients treated with intravenous isosorbide dinitrate. Absorption by route of exposure: Oral: Isosorbide dinitrate is readily absorbed from the oral mucosa and has a short duration of action. Following oral administration it is well absorbed from the gastrointestinal tract. In view of its first pass effect and short plasma half life, slow release formulations are available. Sublingual administration produces maximal concentration of the drug in plasma within 6 minutes. Dermal: Isosorbide dinitrate is also absorbed through the skin from an ointment base. The bioavailability of isosorbide dinitrate is about 29% following oral or sublingual dosing. Distribution by route of exposure: No data available. Biological half-life by route of exposure: The terminal elimination half-life of isosorbide dinitrate is 54.7 minutes, 48.8 minutes and 47.7 minutes respectively following IV injection, sublingual and oral administration. Metabolism: The major route of metabolism of isosorbide dinitrate in man is by enzymatic denitration followed by formation of glucuronides. The primary initial metabolites, isosorbide-2-mononitrate and isosorbide-5-mononitrate have longer half-lives (2-5 hours) and are presumed to be responsible, at least in part, for the therapeutic efficacy of isosorbide dinitrate. A substantial amount of drug can be metabolized due to the "first pass" effect. Elimination by route of exposure: Largely excreted in urine as isosorbide glucuronide. Mode of action: Toxicodynamics: Isosorbide dinitrate has dilator properties on vascular smooth muscle in virtually all vascular beds. Nitrates dilate veins, arteries, and, in high concentrations, arterioles. The beneficial effects in therapeutic doses and the effects seen with overdose are attributable to the physiologic consequences of systemic venous and arteriolar vasodilation. Cardiac preload, systemic blood pressure and systemic vascular resistance all show a progressive decrease. A state of hypotension, circulatory collapse and shock may result. Methemoglobinemia may occur following overdose of isosorbide dinitrate or during therapy. Pharmacodynamics: Organic nitrates can activate guanylate cyclase and increase the synthesis of guanosine 3', 5' - monophosphate (cyclic GMP) in smooth muscle and other tissues. The reactive free radical nitric oxide (NO) is formed which interacts with and activates guanylate cyclase. Interactions: Several important interactions may occur with other cardiovascular drugs. Severe postural hypotension has been observed in patients given isosorbide dinitrate and hydralazine for chronic cardiac failure.Undue dizziness and faintness may occur with sublingual nitrates and beta-adrenoceptor blocking drugs. Complete AV block has been reported after use of sublingual nitrates in patients receiving lignocaine by infusion. Even cardiac asystole may occur. Disopyramide, tricyclic antidepressants and other drugs with anticholinergic effects may prevent dissolution of sublingual isosorbide dinitrate tablets by causing dry mouth. The effects of acetylcholine, epinephrine and histamine can be antagonized by isosorbide dinitrate. An enhanced hypotensive effect may be seen with alcohol. Main adverse effects: The toxic effects of the nitrates are unaffected by the chemical form or by the route of administration and all the nitrates have a common profile of adverse effects. Hypotension, reflex tachycardia and palpitations may occur. Postural hypotension and syncope are seen, especially in elderly patients. Rarely severe bradycardia has been reported. Throbbing headache is quite common. This symptom is likely to recede as tolerance develops. Peripheral edema is also frequently seen. Transient hypoxaemia with precipitation of angina is seen occasionally. Transient cerebral ischemic episodes unrelated to changes in blood pressure are rarely seen. It is therefore advisable to initiate treatment with small doses in patients with cerebrovascular disease. Methemoglobinemia may be seen after therapeutic doses. Weakness, transient dizziness, restlessness and collapse may occur. Cutaneous flushing, perspiration and exfoliative dermatitis have all been reported. Nausea and vomiting are not frequent. Although tolerance has long been associated with nitrates, its clinical implications are not clear. Tolerance is best defined as a decreasing pharmacological effect over time, often with a need for an increasing dose to achieve a given action. Tolerance may be partial or complete and may occur with one type of nitrate therapy and not with others; disappearance of the throbbing headache is a useful sign. However, due to an attenuation of the antihypertensive effect, these agents are not useful in the long term management of hypertension. The part played by the arterial and venous sides of the circulation pertaining to the development of tolerance is not clear. By providing a long (approximately 8 hours) nitrate-free interval, the development of tolerance may be avoided or reduced. Decreasing the number of daily doses of isosorbide dinitrate also helps to achieve this effect. Sustained release preparations are more likely to produce tolerance than the short acting preparations. /Isosorbide dinitrate/

化学と産業

薬理情報

PharmacodynamicsIsosorbide reduces intraocular pressure through its effects on ocular blood vessels. While in the blood, isosorbide promotes redistribution of water toward the circulation, promoting the excretion of urine.
Mechanism of ActionIsosorbide causes vascular relaxation, reducing systolic ophthalmic artery pressure (SOAP), systolic ocular perfusion pressure (SOPP).
Biological Half-Life · 3 件

TEN NORMAL MALES RECEIVED 0.25-1.5 G/KG ISOSORBIDE. DOSE RESPONSE EFFECTS ON WATER & OSMOLAR EXCRETION STATISTICALLY SIGNIFICANT. IN 9 VOLUNTEERS, ORALLY ADMIN ISOSORBIDE APPEARED RAPIDLY IN PLASMA & EXCRETED IN URINE WITH MEAN DISAPPEARANCE HALF-LIFE OF 8 HR.

ISOSORBIDE WAS RAPIDLY ABSORBED BY HUMANS FOLLOWING ORAL ADMIN & WAS EXCRETED UNCHANGED VIA KIDNEY WITH A MEAN DISAPPEARANCE T/2 OF APPROX 7 HR. IT INCREASED URINE VOLUME, CREATININE CLEARANCE, & SODIUM & CHLORIDE EXCRETION.

RABBITS GIVEN ORAL DOSES OF 2 G/KG FOR 1-7 DAYS HAD EST EXCRETION T/2 OF LESS THAN 6 HR IN ALL EYE TISSUE. PEAK LEVEL & EXCRETION T/2 WAS SIMILAR IN DAMAGED & UNDAMAGED EYE TISSUE, EXCEPT IN LENS OF DAMAGED EYES IN WHICH EXCRETION T/2 WAS SHORTER THAN OF NORMAL EYES.

MeSH Pharmacological ClassificationCompounds that increase urine volume by increasing the amount of osmotically active solute in the urine. Osmotic diuretics also increase the osmolarity of plasma.
Absorption, Distribution and Excretion · 2 件

Isosorbide is rapidly absorbed after oral administration. Refer to [isosorbide mononitrate] for detailed absorption information.

IN DOGS, 5.5 MILLIMOLES/KG IV CAUSED LESS SOLUTE EXCRETION THAN AN EQUIMOLAR DOSE OF MANNITOL. THE DISTRIBUTION SPACE OF LABELED ISOSORBIDE WAS 54% OF BODY WT IN INTACT & NEPHRECTOMIZED DOGS. PROXIMAL TUBULAR REABSORPTION OF ISOSORBIDE WAS PROBABLY PASSIVE.

用途と製造

Uses · 2 件

関連反応

36 件
反応記録を作成
HRID 29094 の反応式
HRID 29094生成物として
HRID 61933 の反応式
HRID 61933反応物として
HRID 336060 の反応式
HRID 336060反応物として
HRID 462129 の反応式
HRID 462129反応物として
HRID 462130 の反応式
HRID 462130反応物として
HRID 485097 の反応式
HRID 485097反応物として
HRID 542935 の反応式
HRID 542935反応物として
HRID 542936 の反応式
HRID 542936生成物として
前へ1 / 5 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
屈折率
45 ° · 45 ° (C=5, H2O)
貯蔵温度
Inert atmosphere,Room Temperature
溶解性
DMSO(微量)、メタノール(微量)、水(微量)
外見
結晶、結晶性固体または塊
酸解離定数(Pka)
13.17 · 13.17±0.40(Predicted)
色
オフホワイトからライトイエローまたはベージュ
水溶解度
アルコール、水、ケトンに可溶。
Merck
14 · 14,5224
BRN
80510 · 80510
化粧品成分の機能
スキンコンディショニング保湿剤
InChI
1S/C6H10O4/c7-3-1-9-6-4(8)2-10-5(3)6/h3-8H,1-2H2/t3-,4+,5-,6-/m1/s1
InChIKey
KLDXJTOLSGUMSJ-JGWLITMVSA-N
SMILES
O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12
LogP
-1.39 at · -1.39 at 20℃
CAS データベース
652 · 652-67-5(CAS DataBase Reference)
EPAの化学物質情報
1 · D-Glucitol, 1,4:3,6-dianhydro- (652-67-5)

化学的性質

化学的特性off-white to light yellow or beige crystals,

Isosorbide is relatively safe within the therapeutic range. The oral lethal dose LD50 of isosorbide is 2010 mg/kg in rats and 1771 mg/kg in mice. Lethal dose LD50 of isosorbide has not been a topic of sufficient research in the human population. The symptoms of isosorbide overdose may arise from its vasodilating property causing profound systemic hypotension, heart block with bradycardia, syncope, nausea, vomiting, increased intracranial tension (probably along with persistent throbbing headache, fever, confusion), diaphoresis, dizziness, and palpitations. There is limited clinical information available for the management of isosorbide overdose. The venous hypotension and the arterial hypovolemia of isosorbide overdose can be managed clinically by:

Human Toxicity Excerpts · 3 件

UNTOWARD EFFECTS ARE...SIMILAR /TO GLYCERIN/, ALTHOUGH ISOSORBIDE DOES NOT ADVERSELY AFFECT BLOOD GLUCOSE LEVELS & MAY CAUSE LESS NAUSEA & VOMITING /ORAL ADMIN/.

USE OF ISOSORBIDE STUDIED IN 23 CHILDREN WITH MYELODYSPLASIA & HYDROCEPHALUS. REVERSIBLE MILD TOXICITY INCLUDED LOOSE STOOLS, PALLOR, IRRITABILITY, HYPERNATREMIA, & DOUGHY SKIN.

ISOSORBIDE ADMIN ORALLY IN DAILY DOSES AVG 10 G/KG FOR A MEAN DURATION OF 4 DAYS NOTED ELEVATED SERUM SODIUM OR BLOOD UREA NITROGEN LEVELS, AS OBSERVED IN 26 TRIALS. TOXICITY WAS ALWAYS REVERSED BY DOSAGE ADJUSTMENTS.

Drug Induced Liver Injury · 4 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Isosorbide

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

安全データ

wgk
2
tsca
TSCA listed
rtecs
LZ4380000
hs_code
2934999090
risk_code
22
safety_code
24/25
ストレージクラス
11 - Combustible Solids
有毒物質データの
652-67-5(Hazardous Substances Data)

MEDICATION

MEDICATION (VET)

U.S. Production2023: 80,993 lb
Consumer UsesNot Known or Reasonably Ascertainable
Industry UsesLubricating agent
Methods of ManufacturingPREPARED BY ACID DEHYDRATION OF D-GLUCITOL: HAWORTH, WIGGINS, BRITISH PATENT 600,870 (1948). PURIFICATION: HARTMANN, US PATENT 3,160,641 (1964 TO ATLAS CHEM INDUSTRIES).
Formulations/PreparationsISMOTIC (ALCON), ORAL AS 45% SOLUTION.
General Manufacturing Information · 3 件

Plastics Material and Resin Manufacturing

D-Glucitol, 1,4:3,6-dianhydro-: ACTIVE

A POLYOL WITH HYDROXYL GROUP ATTACHED TO EACH OF TWO CIS-ORIENTED SATURATED FURAN RINGS.

応用分野

用途その他の利尿薬尿細管内の浸透圧を上昇させることで水の再吸収を抑制する

使用Isosorbide is a reagent widely used to prepare detergents, cleansers, cosmetics, agrochemicals and vasodilators.

上流・下流製品情報

上流原料

D-Sorbitolグルシトール3,6-アンヒドロ-D-グルシトール

下流製品

イソソルビドジメチルエーテルD-Iditol, 2,5-anhydro-Hexitol, 2,5-anhydro-1,3,7-オクタトリエンテトラヒドロフラン2,2-Dimethyl-4-(2-oxiranyl)tetrahydrofuro[3,4-d][1,3]dioxole5-硝酸イソソルビド

補足説明

定義A polyol with a hydroxyl group attached to each of two cis-oriented saturated furan rings. Intermediate for pharmaceuticals. Combustible.